JAK2 and acquired polycythemia vera: These alterations result from an abnormal signal transduction, secondary to mutations in genes encoding tyrosine kinase proteins or related molecules (BCR-ABL1 fusion gene in CML and JAK2 V617F mutation in polycythemia vera) [7].